[IPO] Sunbio “Leap to Become a Global Leading Company in Pegylation Technology”

[Asia Economy Reporter Jang Hyowon] Sunbio (CEO Noh Kwang), the only domestic bio company specializing in PEGylation technology, held an online press conference on the 16th to introduce the company and its growth strategy after listing.

Founded in 1997, Sunbio is the only domestic bio company developing and applying PEGylation technology. PEGylation technology chemically attaches PEG derivative materials to the surface of target substances through covalent bonds, enhancing the effects of the target substances. By utilizing this technology, effects such as ▲increased blood half-life ▲reduced immune response and antigenicity ▲toxicity mitigation ▲improved structural stability can be applied to target substances.

Sunbio's core competencies are ▲ability to commercialize high-quality PEG derivative materials ▲PEGylation specialized pipeline built over 20 years of experience ▲possession of global standard production facilities.

Sunbio possesses capabilities ranging from development and production of PEG derivatives to commercialization using PEGylation technology. It directly produces and sells over 200 types of PEG derivatives with high purity and activity, and through PEGylation technology, it commercializes products such as biosimilars and new biopharmaceuticals. As a result, it has established pipelines including ▲biosimilar for neutropenia treatment ▲dry mouth treatment (MucoPEG) ▲artificial blood ▲cartilage synovial fluid filler ▲gout treatment.

Sunbio's representative pipeline is the biosimilar for neutropenia treatment, for which it has signed a technology transfer and PEG derivative material supply contract with the Indian multinational pharmaceutical company Intas Pharmaceuticals Ltd., receiving royalties and sales revenue.

The dry mouth treatment has received 510(k) medical device marketing approval from the US FDA and is conducting comparative clinical trials in the US for overseas technology transfer. In the mid to long term, Sunbio plans to secure future growth engines by developing artificial blood, cartilage synovial fluid fillers, and gout treatments applying PEGylation technology.

Sunbio owns global standard production facilities. Through GMP (Good Manufacturing Practice) certified production facilities and DMF (Drug Master File) registration, it enhances the reliability of PEG derivative quality. Subsequently, by relocating production facilities to the Incheon plant, it plans to expand PEG derivative production capacity from the current maximum annual total production scale of about 200kg to up to 5,000kg. This production capacity expansion is expected to increase Sunbio's sales.

CEO Noh Kwang of Sunbio stated, “Sunbio will grow significantly based on the pipeline built over the past 20 years,” and added, “We will continuously enhance our expertise after listing to become a global leading company in the field of PEGylation technology applications.”

Meanwhile, Sunbio plans to offer a total of 616,000 shares. The desired public offering price band is 14,000 to 16,000 KRW, with an expected offering amount of 8.6 to 9.9 billion KRW. Demand forecasting for institutional investors will be held on the 16th and 19th, followed by general subscription from the 22nd to 23rd, and the company is scheduled to be listed on the KOSDAQ market in early October. The lead underwriter is Hana Securities.

This content was produced with the assistance of AI translation services.